Display options
Cite
H Abdelnaby M. Effect of Percutaneous Coronary Intervention on Heart Rate Variability in Coronary Artery Disease Patients. Eur Cardiol. 2018;13(1):60-61doi: 10.15420/ecr.2018.13.2.
H Abdelnaby, M. (2018). Effect of Percutaneous Coronary Intervention on Heart Rate Variability in Coronary Artery Disease Patients. European cardiology, 13(1), 60-61. https://doi.org/10.15420/ecr.2018.13.2
H Abdelnaby, Mahmoud. "Effect of Percutaneous Coronary Intervention on Heart Rate Variability in Coronary Artery Disease Patients." European cardiology vol. 13,1 (2018): 60-61. doi: https://doi.org/10.15420/ecr.2018.13.2
H Abdelnaby M. Effect of Percutaneous Coronary Intervention on Heart Rate Variability in Coronary Artery Disease Patients. Eur Cardiol. 2018 Aug;13(1):60-61. doi: 10.15420/ecr.2018.13.2. PMID: 30310473; PMCID: PMC6159452.
Copy Download .nbib Format: NLM
Share it on

Eur Cardiol. 2018 Aug;13(1):60-61. doi: 10.15420/ecr.2018.13.2.

Effect of Percutaneous Coronary Intervention on Heart Rate Variability in Coronary Artery Disease Patients.

European cardiology

Mahmoud H Abdelnaby

Affiliations

  1. Medical Research Institute, Alexandria University Alexandria, Egypt.

PMID: 30310473 PMCID: PMC6159452 DOI: 10.15420/ecr.2018.13.2

Abstract

Patients with coronary artery disease (CAD) have a state of autonomic imbalance with a sympathetic predominance. Autonomic dysfunction has been linked to an increased risk of cardiovascular morbidity and mortality. Heart rate variability (HRV) analysis is one of the most encouraging non-invasive diagnostic models and is increasingly used for the assessment of autonomic dysfunction. Percutaneous coronary intervention (PCI) is considered the gold standard in CAD treatment. Revascularisation through PCI eliminates the state of sympathetic hyperactivity, restores the normal cardiac autonomic modulation that can be assessed by HRV measurement.

Keywords: Coronary artery disease; heart rate variability; percutaneous coronary intervention

Conflict of interest statement

Disclosure: The author has no conflict of interest to declare.

References

  1. Kardiol Pol. 2003 Jan;58(1):10-6 - PubMed
  2. Am J Crit Care. 1994 Nov;3(6):476-80 - PubMed
  3. Pol Merkur Lekarski. 2005 Oct;19(112):548-52 - PubMed
  4. Eur Heart J. 2014 Nov 7;35(42):2950-9 - PubMed
  5. Eur Rev Med Pharmacol Sci. 2009 Jul-Aug;13(4):299-307 - PubMed
  6. Int Arch Med. 2012 Oct 30;5(1):31 - PubMed
  7. Am J Cardiol. 2000 Apr 1;85(7):815-20 - PubMed
  8. Przegl Lek. 2002;59(9):695-8 - PubMed
  9. Swiss Med Wkly. 2004 Sep 4;134(35-36):514-22 - PubMed
  10. J Am Coll Cardiol. 1991 Sep;18(3):687-97 - PubMed
  11. Br Heart J. 1992 May;67(5):387-91 - PubMed
  12. Anatol J Cardiol. 2015 Jun;15(6):496-501 - PubMed
  13. J Tehran Heart Cent. 2015 Apr 3;10(2):80-4 - PubMed
  14. Cardiovasc J Afr. 2009 Jul-Aug;20(4):240-4 - PubMed

Publication Types